In Alzheimer's disease (AD), cholinergic dysfunction (often with reduced acetylcholine tone and impaired choline metabolism) is linked with cortical dysfunction, memory deficit, abnormal cerebral blood flow, task learning difficulty, sleep-cycle disruption, and neurodevelopmental effects (context-dependent).
CORE HALLMARKS / HIGH-CONFIDENCE AXES:
- tau and Aβ, their accumulation in AD brains is known to be a major hallmark.
In AD, PP2A↓ activity is decreased (reported), contributing to hyperphosphorylated tau accumulation.
SIRT-1↓ levels in AD brains are associated with accumulation of Aβ and tau (reported).
- glucose metabolism↓ (brain glucose hypometabolism) occurs in AD long before significant clinical signs in many cohorts/models (reported).
- Neuroinflammation / lipid mediator tone (reported): 5-LOX↑ and PGE2↑ (model-/region-dependent).
- Synaptic vulnerability (reported): PSD95↓ in hippocampus and cortex; restoring PSD95 shows cognitive benefits in models.
- Clearance/transport imbalance (reported): IDE↓, NEP↓, LRP1↓, and AEP↑ protein levels in AD brains (reported).
COMMONLY REPORTED DIRECTIONAL CHANGES (model/region/compartment dependent):
- Monoamines (reported): concentrations of 5-HTP↓, 5-HT(seratonin)↓, and 5-HIAA↓ are lower in Alzheimer's patients (varies by region/study).
- Cholinergic system (clinical target): reduction in ACh↓ production; ChAT↓ activity reduced (synthesizes ACh).
- Four key enzymes frequently targeted in AD symptom/adjunct strategies:
AChE,
BChE,
MAOA,
MAOB (objective inhibit).
- Neurotrophic tone (reported): BDNF↓ in key regions.
- Stress can decrease expression of brain-derived neurotrophic factor (BDNF).
- Kinase/protease stress (reported): CDK5↑ hyperactivation; calpain↑ overactivated by increased intracellular Ca²⁺ → p-tau and aggregation.
- Aβ-linked synaptic regulator (reported): STEP↑ upregulated largely due to Aβ oligomer accumulation.
- α-secretase axis (reported): ADAM10↓ downregulated in AD brains.
- Metabolic cofactors (reported): ALC↓ (ALCAR); Homocarnosine↓ (CSF declines with age); possible low Taurine↓ (age-related + dementia reports).
- Ion/glutamate handling (reported): impaired glutamate clearance + depressed Na+/K+ ATPase → cellular ion imbalance risk.
- Aging reduces NAD⁺↓ (in AD depletion may be more severe).
- Mitochondrial capacity axis (reported): PGC-1↓ decreased in Alzheimer’s brains.
- Innate immune DNA-sensing axis (animal): cGAS–STING↑ elevation observed in AD mice and normalized by NR treatment.
- Vascular/structure (reported): a profound change in BBB permeability; progressive brain shrinkage (atrophy).
- Glycation axis (reported): AGEs↑ and RAGE↑ expression.
HOMOCYSTEINE / B-VITAMIN AXIS:
- Raised plasma total homocysteine (tHcy)↑ associated with cognitive impairment, AD, or vascular dementia (epidemiology).
- Homocysteine can build up if vitamin B6, B12, or folate levels are low.
- Homocysteine and B-vitamin in Cognitive Impairment (VITACOG) study.
- Vit B6 might be an important B vitamin (often discussed along with B12 and folate).
- Thiamine↓ deficiency produces a cholinergic deficit (well-aligned with AD features).
- Decreased thiamine (B1) in AD may exacerbate Aβ deposition, tau hyperphosphorylation, and oxidative stress (reported).
MICRONUTRIENTS / CAROTENOIDS (reported; compartment-dependent):
- vitamin A↓ and β-carotene↓ lower in some AD cohorts; excess retinol may contribute to osteoporosis risk.
- Diminished circulating vitamin E↓ reported in AD.
- Vitamin B5↓ in multiple brain regions (reported).
- Trace elements: patients with AD reported lower serum Se, Cu, and Zn↓ (serum findings vary by study).
- Brain metals: some studies report higher brain copper↑ and iron↑ in specific regions/structures; compartment and region matter.
Rosmarinic acid reported to reduce copper-induced neurotoxicity in vitro/in vivo and may interfere with amyloid–copper interactions (preclinical).
- SAMe↓ concentrations in CSF reported in AD.
- MPOD often reduced in AD patients.
- AD brains reported lower levels of
lutein↓,
zeaxanthin↓,
anhydrolutein↓,
(VitA)retinol↓,
lycopene↓,
alpha-tocopherol↓.
RISK CONTEXT:
- Apolipoprotein E4 (ApoE4) genotype is the strongest known genetic risk factor for late-onset AD.
- One copy of ApoE4: ~3–4× increased risk (range varies by cohort).
- Two copies: ~8–12× increased risk (range varies).
- VitK lower in circulating blood of APOE4 carriers (reported).
- Type 2 diabetes, traumatic brain injury, stroke, diet, and above all, aging is the number ONE risk factor.
Treatments / Strategy Targets (high-level):
- Early intervention tends to have a greater positive effect than interventions during middle or late stages.
- BOLD fMRI imaging can be used to observe brain activity via blood oxygen/flow changes.
- Reduce ROS and inflammation in the brain (context-dependent; avoid over-suppressing adaptive signaling).
- Inhibiting acetylcholinesterase (AChE) (which breaks down ACh), e.g., donepezil, rivastigmine.
- Natural AChE inhibitors include:
Berberine,
Luteolin,
Crocetin(saffron),
Querctin,
TQ
- Natural AChE inhibitors in database (check BBB pass potential).
- MAOB inhibitors,
APP inhibitors,
PGE2 inhibitors,
NLRP3 inhibitors,
BACE inhibitors
- BDNF activators,
PSD95 activator
- STEP,
ADAM10
- Diets with an adequate ratio (5:1) of omega-6:3 (Mediterranean diet).
- Vitamins B1, B6, B12, B9 (folic acid) and D, choline, iron and iodine exert neuroprotective effects (general nutrition framing).
- Antioxidants (vitamins C, E, A, zinc, selenium, lutein and zeaxanthin).
- Fiber may promote gut microbiome diversity influencing brain health.
- Supplementing with NAD⁺ precursors (NR or NMN) improves cognition and reduces amyloid/tau pathologies in AD mice (animal evidence).
- "It is advisable to consume diets with an adequate ratio (5:1) of omega-6:3 fatty acids (Mediterranean diet) ... antioxidants ... role in oxidative stress ... cognition."
Nutrition Strategies
- Reduction of cognitive decline may be achieved by following a healthy dietary pattern limiting added sugars while maximizing fish, fruits, vegetables, nuts, seeds.
Related Pathways to research in this database (products that modulate them):
- neuroprotective,
cognitive,
memory
- Aβ aggregation,
Tau↓,
AChE↓,
ACh↑,
ChAT↑,
acetyl-CoA↑,
BDNF↑,
BACE↓,
NLRP3↓,
PSD95↑,
PGE2↓,
homoC↓
- Increasing AntiOxidants:
Catalase↑,
GSH↑,
SOD↑,
HO-1↑, to decrease
ROS↓
- Lower Inflammation:
TNF-α↓,
IL1β↓,
IL6↓
Natural Products that may benefit AD.
-Some key pathways are highlighted in RED in the following links
Acetyl-L-carnitine,
ALA,
Apigenin,
Anthocyanins Blueberrys,
Aromatherapy,
Artemisinin,
Ashwagandha,
β-carotene(vitamin A),
Bacopa monnieri,
Baicalein,
Baicalin,
Berberine,
Betulinic acid,
Boron,
Boswellia (frankincense),
Caffeic acid,
Caffeine,
Capsaicin,
Carnosine,
Carnosic acid,
Chlorogenic acid,
Choline,
Chrysin,
Cinnamon,
CoQ10,
Crocetin,
Curcumin,
dietMed,
dietMet,
dietSTF,
EGCG,
Ellagic acid,
Exercise,
Ferulic Acid,
Fisetin,
Flav,
FLS,
Folic Acid (5-MTHF, L-methylfolate)-reduce homocysteine,
Galantamine,
Ginger,
Ginkgo biloba,
Ginseng,
Honokiol,
Huperzine A,
hydrogen gas,
Lecithin,
Lutein,
Luteolin,
Lycopene,
M-Blu,
Moringa oleifera,
Mushroom Lion’s Mane,
MSM,
MCToil,
NAD,
Naringenin,
PEMF,
Piperine,
Phenylbutyrate,
Phosphatidylserine,
Piperlongumine,
Potassium,
probiotics,
Propolis,
Pterostilbene,
Quercetin,
Resveratrol,
Rivastigmine,
Rosmaric Acid(reduce copper-induced neurotoxicity),
Rutin,
Safflower yellow,
Sage,
SAMe,
selenium,
Serotonin,
Shankhpushpi,
Shikonin,
Shilajit/Fulvic Acid,
silicon(reduce Alum bioavialability),
Silymarin (Milk Thistle) silibinin,
Sulforaphane,
Taurine,
TQ,
Ursolic Acid
Vitamin B1,
Vitamin B2,
Vitamin B3,
Vitamin B5,
Vitamin B6,
Vitamin B12,
Vitamin E,
Vitamin D,
Vitamin K2
Zeaxanthin,
zinc,
Aluminium
has a negative impact on cognition but silicon can decrease Alumunium bioavailability, and Vitamin K2 may provide some protection. Example
So does RMF
Brain Energy Systems Matrix (AD)
Tier 1–2 as “core metabolic cofactors / redox pools”
Tier 4 as “alternative fuels / bypass strategies”
Tier 5–6 as “capacity + delivery constraints” (often explains why supplements don’t translate)
| Tier |
Rank |
Node / Lever |
What it Supports (Bioenergetic Role) |
Key Enzymes / Targets |
AD-Relevant Mechanism |
TSF |
Evidence |
Common Constraints / Gotchas |
| 1 | 1 |
Thiamine (B1) / TPP |
Glucose → acetyl-CoA entry + TCA throughput + NADPH support |
PDH, α-KGDH, Transketolase (PPP) |
Addresses cerebral glucose hypometabolism; improves mitochondrial flux; PPP→NADPH supports redox |
R, G |
Mechanistic + small clinical |
Benefit strongest if low status; standard thiamine vs lipophilic derivatives differ |
| 1 | 2 |
Benfotiamine |
Higher-bioavailability B1 strategy |
Transketolase ↑; glycation axis ↓ |
AGE/RAGE burden reduction + metabolic support (model/trial dependent) |
G |
Small clinical + mechanistic |
Not a “rapid” effect; mostly longer-term metabolic/toxicity load reduction |
| 1 | 3 |
Riboflavin (B2) / FAD, FMN |
ETC redox enzymes + mitochondrial dehydrogenases |
Complex I/II flavoproteins; many oxidoreductases |
Supports electron handling; can be limiting in mitochondrial enzyme insufficiency |
R, G |
Mechanistic |
Direct AD cognitive trial support limited; “helps” mostly when deficient or enzyme-limited |
| 1 | 4 |
Niacin forms (B3) → NAD pool |
NAD+/NADH redox + signaling + repair |
NAD salvage; sirtuins; PARP substrate |
NAD decline is an aging/inflammation theme; supports mitochondrial redox capacity |
R, G |
Emerging human + mechanistic |
Different forms behave differently; NAD raising ≠ guaranteed clinical cognition benefit |
| 1 | 5 |
Pantothenic acid (B5) → CoA |
Acetyl-CoA formation; lipid metabolism; TCA entry |
CoA biosynthesis; acetylation capacity |
Foundational for fuel oxidation and acetylation balance |
G |
Mechanistic |
Often overlooked; deficiency uncommon but suboptimal intake can matter in frailty |
| 1 | 6 |
Magnesium |
ATP handling (Mg-ATP) + enzyme kinetics |
ATP-dependent enzymes; synaptic function |
Supports neuronal energy usage + plasticity; deficiency can worsen excitotoxic vulnerability |
R, G |
Supportive human + mechanistic |
Form/absorption variability; renal constraints for supplementation in some patients |
| 2 | 1 |
NAD+ precursors (NR/NMN/NA/NAM) |
Restores NAD+ availability for redox + signaling |
NAMPT salvage; sirtuins; PARPs; CD38 |
Supports mitochondrial function; may improve resilience under oxidative/repair load |
R, G |
Animal > human (emerging) |
NAD “sinks” (CD38/PARP) can dominate; response varies by inflammation/age |
| 2 | 2 |
Alpha-lipoic acid (ALA) |
Mitochondrial redox cofactor + antioxidant recycling |
PDH/α-KGDH cofactor; GSH recycling support |
Improves redox tone and mitochondrial efficiency (signals strongest in metabolic/oxidative phenotypes) |
R, G |
Small AD trials + mechanistic |
“Antioxidant” framing can be misleading—main value is mitochondrial/redox coupling support |
| 2 | 3 |
Glutathione system support |
Detox + peroxide handling |
GSH, GPx, GR, NADPH supply (PPP) |
Reduces oxidative damage load that impairs mitochondria/synapses |
R, G |
Mechanistic |
GSH depends on substrates + NADPH; pushing one component may not fix system |
| 2 | 4 |
Selenium (GPx capacity) |
Peroxide detox via selenoenzymes |
Glutathione peroxidases |
Supports antioxidant enzyme capacity (context-dependent) |
G |
Mixed human |
Narrower safety margin; avoid “more is better” mindset |
| 3 | 1 |
CoQ10 (ubiquinone) |
ETC electron carrier (I/II→III) + membrane redox |
Complex I/II→III transfer |
Supports OXPHOS efficiency; may reduce electron leak under some conditions |
R, G |
Limited AD-specific |
Bioavailability/formulation matters; AD cognition data not robust |
| 3 | 2 |
Cardiolipin / mitochondrial membranes (support axis) |
ETC supercomplex stability; cristae integrity |
Inner mitochondrial membrane architecture |
Membrane integrity affects ETC efficiency and ROS leak |
G |
Mechanistic |
Hard to “target” nutritionally in a clean way; effects indirect |
| 3 | 3 |
Iron / copper homeostasis (burden control) |
Prevents metal-catalyzed oxidative damage |
Fenton chemistry burden; metal transport/storage |
Metal dyshomeostasis can amplify ROS and mitochondrial injury |
R, G |
Mechanistic + mixed human |
“Chelation” is not casually safe; needs careful framing and evidence |
| 4 | 1 |
Ketone utilization (BHB/acetoacetate axis) |
Alternative brain fuel bypassing glucose bottlenecks |
MCT1/2 transport; ketolysis enzymes |
Addresses brain glucose hypometabolism by providing alternate substrate |
R, G |
Moderate (human MCI/AD signals exist) |
GI tolerance and adherence; response varies by genotype/metabolic status |
| 4 | 2 |
Creatine / phosphocreatine shuttle |
ATP buffering and rapid energy stabilization |
Creatine kinase system |
May stabilize energy during stress; supports muscle/functional reserve that impacts cognition indirectly |
G |
Limited AD |
CNS benefit uncertain; stronger for muscle/functional outcomes |
| 4 | 3 |
Acetyl-L-carnitine (ALCAR) |
Fatty acid oxidation support + acetyl group handling |
Carnitine shuttle; acetyl-CoA support |
May support mitochondrial energy and neuronal function (mixed clinical results) |
R, G |
Mixed human |
Benefits heterogeneous; not a universal cognitive improver |
| 4 | 4 |
Medium-chain triglycerides (MCT oil → ketones) |
Rapid ketone support strategy |
Hepatic ketogenesis; brain ketone uptake |
Practical ketone-raising approach for some phenotypes |
R, G |
Moderate human |
GI effects; calorie load; titration matters |
| 5 | 1 |
AMPK → PGC-1α biogenesis axis |
Mitochondrial number/quality regulation |
AMPK, PGC-1α, SIRT1 |
Supports long-term mitochondrial capacity and stress resistance |
G |
Mechanistic |
Most effects are slow; many “activators” are indirect and context-dependent |
| 5 | 2 |
Mitophagy / autophagy quality control |
Removes damaged mitochondria |
PINK1/Parkin axis; autophagy machinery |
Damaged mitochondria drive ROS and energy failure; quality control is protective in theory |
G |
Mechanistic |
Autophagy modulation is double-edged; oversimplified “more autophagy = good” is risky |
| 5 | 3 |
Exercise signaling (the “master cofactor”) |
Improves vascular + mitochondrial + neurotrophic tone |
BDNF; insulin sensitivity; AMPK/PGC-1α |
Most evidence-backed multi-pathway energy intervention for aging brain |
R, G |
Strong (human) |
Adherence/ability constraints; must be individualized |
| 6 | 1 |
Cerebral perfusion / vascular health |
Fuel + oxygen delivery and waste clearance support |
Neurovascular unit; endothelial function |
Vascular dysfunction worsens hypometabolism and inflammation |
R, G |
Strong (human) |
Often upstream of “supplement” efficacy; if delivery is poor, cofactors underperform |
| 6 | 2 |
Sleep / glymphatic clearance |
Waste clearance & metabolic recovery |
Glymphatic system; circadian regulation |
Supports clearance of metabolic byproducts; indirectly supports energy balance |
G |
Strong (human) |
Often neglected; impacts cognition and inflammation strongly |
| 6 | 3 |
Oxygen utilization context (respiratory capacity) |
Oxidative metabolism support |
OXPHOS dependence |
If oxygen delivery/usage is limited, pushing mitochondrial cofactors won’t fully translate |
R, G |
Supportive |
More about system constraints than a “node to supplement” |
TSF (Time-Scale Flag): P = 0–30 min, R = 30 min–3 hr, G = >3 hr (adaptation/phenotype).
Evidence: "Strong (human)" = consistent clinical/epidemiologic support; "Moderate" = mixed but plausible human signals; "Emerging" = early-stage human; "Mechanistic" = preclinical/biochemical rationale.
|